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A Novel Method to Isolate Mesenchymal Stem Cells
from Bone Marrow in a Closed System Using
a Device Made by Nonwoven Fabric
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Eishi Ashihara, M.D., Ph.D.,4 Shinya Kimura, M.D., Ph.D.,4 Taira Maekawa, M.D., Ph.D.,4
Akira Kobayashi, Ph.D.,5 Shinya Yoshida, Ph.D.,5 Hideo Niwa, Ph.D.,5 Takanobu Otsuka, M.D., Ph.D.,2
Takashi Nakamura, M.D., Ph.D.,3 and Junya Toguchida, M.D., Ph.D.1
Bone marrow stromal cells (BMSCs) include cells with multidirectional differentiation potential described as
mesenchymal stem cells. For clinical use, it is important to develop a way to isolate BMSCs from bone marrow in
a closed system without centrifugation. After screening 200 biomaterials, we developed a device containing a
nonwoven fabric filter composed of rayon and polyethylene. The filter selectively traps BMSCs among mono-
nuclear cells in bone marrow based on affinity, not cell size. The cells are then recovered by the retrograde flow.
Using canine and human bone marrow cells, the biological properties of BMSCs isolated by the device were
compared with those obtained by conventional methods using centrifugation. The total number isolated by the
device was larger, as was the number of CD106þ=STRO-1þ double-positive cells. The cells showed osteogenic,
chondrogenic, and adipogenic differentiation potential in vitro. Finally, the direct transplantation of cells isolated
by the device without in vitro cultivation accelerated bone regeneration in a canine model of osteonecrosis in vivo.
The proposed method is rapid and efficient, does not require a biological clean area, and will be useful for the
clinical application of mesenchymal stem cells in bone marrow.
Introduction
Bone marrow stromal cells (BMSCs) include cellswith multidirectional differentiation potential such as
mesenchymal stem cells (MSCs), multipotent adult progen-
itor cells, and marrow-isolated adult multilineage inducible
cells, although it is not yet clear whether these cell types
are distinct or overlap.1,2 In spite of such ambiguity, BMSC-
derived multipotent cells have been used in various fields of
regenerative medicine. For clinical applications, however, it
is critical to develop a method separating BMSCs containing
multipotent cells from other types of cells in bone marrow
that is simple, safe, inexpensive, and achievable in a closed
system. The most popular way to isolate BMSCs is the
density gradient method using a detergent such as sucrose3
although the process is technically demanding and time
consuming. Simple centrifugation with low gravity can also
separate mononuclear cells (MNCs) from erythrocytes, and
BMSCs can be selected through adherence to plastic dishes.4
This method, however, still needs centrifugation, which
makes it difficult to perform in a closed system, and therefore
requires a biologically clean room.
To avoid the need for centrifugation, we have attempted
to develop a device that can isolate BMSCs by filtration, and
have selected nonwoven fabrics as biomaterials. Nonwoven
fabrics are engineered materials that provide specific func-
tions such as absorbency, liquid repellency, resilience,
stretch, softness, strength, flame retardancy, washability, and
cushioning.5 As for clinical applications, nonwoven fabrics
are used mainly for two purposes, as scaffolds and filters. A
number of studies have used nonwoven fabrics as scaffolds
for tissue regeneration.5–7 The material and diameter of the
fabric are important for cell attachment.6,8 For example,
polyethylene terephthalate with fibers 9.0 mm in diameter is
ideal for the osteogenic differentiation of MSCs.6 As filters,
nonwoven fabrics have been used to sterilize medical ma-
terials.9 Lymphocytapheresis is a form of treatment for pa-
tients with autoimmune diseases, in which lymphocytes in
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peripheral blood are removed to reduce immunoreactions.
To replace the centrifugation process in lymphocytapheresis,
a filtration method using nonwoven fabrics has been devel-
oped.10 The trapping effect is attributed to the affinity of the
material for cells and the size of the material’s fibers, with
almost all leukocytes trapped when the fibers are less than
3 mm in diameter.10,11
As pure mechanical trapping based on cell size can dam-
age cell membranes, we have tried to develop a filter that
traps MSCs through affinity and here show that a new de-
vice composed of rayon–polyethylene nonwoven fabrics can
isolate BMSCs from bone marrow aspirates, which contain
cells compatible with multipotent cells in vitro and in vivo.
Materials and Methods
Screening of materials
The basic concept behind our approach is to trap BMSCs
amongbonemarrowaspirates on afilter, and collect themusing
a retrograde flow (Fig. 1A). Biomaterials for the filter were
screened based on microscopic structure (evenness), diameter
(over 10mm), weight (over 50g=m2), bio-safety, and availability
(as the first screening). Potentially suitable biomaterials were
further screened by conducting colony-forming unit (CFU) as-
says described later using swine bone marrow cells in three
steps (as the second, third, and fourth screening; Supplemental
Fig. S1, available online at www.liebertonline.com).
Electron microscopic analyses
After bone marrow had permeated through it, the filter
was treated with 2.5wt% glutaraldehyde in saline for 2 days
at 48C. The samples were dried by passing them through a
series of graded-alcohol-saline solutions. Finally, the solution
was changed to 100% t-butanol, and the samples were
freeze-dried for 10 h at 58C. The dried membranes were
coated with gold–palladium and examined using a S-3000N
scanning electron microscope (Hitachi, Tokyo, Japan).
Harvesting of bone marrow
Humans. Ten milliliters of bone marrow was taken from
iliac crests of donors who received orthopedic operative
procedures requiring autologous bone grafts from iliac
crests. The donors had no history of concurrent illness or of
medication that could affect bone metabolism. The Ethics
Committee of the Faculty of Medicine, Kyoto University,
approved the procedure, and informed consent was obtained
from each donor according to the declaration of Helsinki.
Dogs. Ten milliliters of bone marrow was aspirated from
iliac crests of male beagle dogs (10–13 kg) under intravenous
anesthesia. The experiments with animals were approved by
the institutional animal research committee, and performed
according to the Guidelines for Animal Experiments of
Kyoto University.
Preparation of MNCs
Human marrow samples were divided equally into three
aliquots (3mL each). One aliquot was applied to the device
(method D), which had been saturated with saline. After
washing the filter with 10mL of saline, trapped cells were
collected by a retrograde flow of the culture medium into a
collection bag (Fig. 1A). The second aliquot was suspended
in 5mL of a-minimum essential medium GlutaMAX
(Invitrogen, Carlsbad CA,) with 10% fetal bovine serum
(Hyclone, South Logan, UT). The suspension was centri-
fuged at 1200 rpm for 5min. The supernatant and the buffy
coat were re-suspended in another tube with 5mL of a-
minimum essential medium GlutaMAX with 10% fetal bo-
vine serum. This method is hereafter designated method S
(simple centrifugation).4,12 The final aliquot of bone marrow
was fractionated by centrifugation over a density cushion
using a Ficoll gradient (GE Healthcare Life Sciences, Piscat-
away, NJ), as described.3 The interface layer was harvested
and washed twice with 10mL of Hank’s buffer solution. This
method is hereafter designated method F (Ficoll gradient).
Collection efficacy
Cells trapped on the filter and collected by retrograde flow
in the collection bag were designated the collected fraction,
and cells flowing through the filter into the flow-through bag
were designated the flow-through fraction (Fig. 1A). Col-
lection efficacy was determined as the ratio of the number of
cells in each fraction to that in the applied bone marrow.
CFU assay
For the CFU assay, the MNCs were diluted and plated in 60-
mm cell culture dishes at a density of 2.5105 cells=dish and
incubated for 14 days (n¼ 3). The cells were fixed with meth-
anol and stained with a 0.05% crystal violet solution. We
counted the number of colonywith a diameter more than 4mm.
Flow cytometry
Cells were stained at room temperature for 30min with
the following antibodies: CD10-phycoerythrin (PE), CD34-
allophycocyanin (APC), CD45-peridinin chlorophyll protein
(PerCP-Cy5.5), CD106-fluorescein isothiocyanate (FITC),
CD166-PE (BD Biosciences, San Jose, CA), CD90-FITC (Beck-
man Coulter, Fullerton, CA), CD271-APC (Miltenyi Biotec,
Bergisch Gladbach, Germany), and STRO-1-PE (Santa Cruz
Biotechnology, Santa Cruz, CA). They were subsequently
subjected to flow cytometry using a FACS Calibur instrument
(BD Biosciences).
Induction of differentiation and histochemical evaluating
Differentiation was induced using the standard method.13
The differentiation potential was evaluated as below.
Osteogenic differentiation: Calcified nodules were evalu-
ated by alizarin red staining, and calcium content was
quantified.
Adipogenic differentiation: Intracellular lipid droplets
were stained with oil red-O, and the amount of triglyc-
eride was quantified.
Chondrogenic differentiation: Cartilage matrix was eval-
uated by alcian blue staining, and the amount of gly-
cosaminoglycan was quantified.
These analyses were described previously.14
Reverse transcription–polymerase chain reaction
Total RNA was extracted using RNeasy Kit (Qiagen, Hil-
den, Germany). All reverse transcription reactions were
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performed using the Super Script First Strand Synthesis
System (Invitrogen). Polymerase chain reaction amplification
was carried out using rTaq polymerase (Toyobo, Osaka,
Japan). All polymerase chain reactions were performed using
GeneAmp 9700 (PE Applied Biosystem, Foster City, CA) and
specific primers for each gene.14
Preparation of the canine model
of osteonecrosis and cell transplantation
A canine model of scapho-lunate osteonecrosis was pre-
pared as described previously.15 Briefly, scapho-lunates on
one side were exposed dorsally, and a cortical window of
510mmwas made, through which as much cancerous bone
as possible was removed. After the curettage, the cavity was
filled with liquid nitrogen for 10min, and the frozen bone
was thawed at room temperature for 10min. This freeze–
thaw procedure was repeated three times. On one side, the
bone cavity was filled with beta-tricalcium phosphate (b-
TCP) granules (200mg, 0.2 cm3) (Osferion; Olympus, Tokyo,
Japan) (hereafter designated the control side). On the other
side, canine BMSCs (6.0107 1.5107) isolated by the de-
vice from 10mL of bone marrow were mixed with the same
amount of b-TCP and transplanted into the bone cavity
(hereafter designated the BMSC side). Finally, the bone
window was plugged with 510mm cortical bone. Animals
were sacrificed and evaluated at 4 weeks after the operation
(n¼ 6).
FIG. 1. Device containing a nonwoven fabric filter. (A) Photo of the device and schematic explanation of the collection
method. The red line indicates the orthograde flow to apply bone marrow, and the blue line indicates the retrograde flow to
collect cells. Scale bar¼ 30mm. (B) Electron micrograph of the nonwoven fabric of rayon and polyethylene. Arrow, rayon;
arrowhead, polyethylene. Magnification, 2000. Scale bar¼ 20mm. (C) Conditioning of flow velocity using swine bone
marrow. Closed circles and closed triangles indicate the number of colony-forming units (CFUs) formed by cells in the
collected fraction and flow-through fraction at the indicated flow velocity, respectively. (D) Electron micrograph of the
surface of the filter after the orthograde flow of swine bone marrow (a) and after the retrograde flow of collection medium (b).
Magnification, 2500. Scale bar¼ 20mm.
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Imaging analyses
X-ray. Antero-posterior and lateral views of both wrists
were obtained. The carpal height ratio was calculated from
the antero-posterior view.15,16 The Sta˚hl index was calculated
from the lateral view.15,17
Micro-computed tomography. Canine carpal bones were
scanned by computed tomography (CT) (SMX-100CT-SV3
type; Shimazu, Kyoto, Japan). The image consisted of 800
slices with a voxel size of 68.224mm in all three axes. Coronal
and sagittal cross-sectional views of the scapho-lunate were
reconstructed using adjunctive software. The same setting
was used for all samples. The image reconstruction and
quantification of the scapho-lunate were performed with VG
Studio MAX software (Nihon Visual Science, Tokyo, Japan).15
Macroscopic and microscopic assessments
The volume and weight of extracted scapho-lunate bones
were actually measured using a scale. The samples were
fixed in a 10% formalin solution, decalcified with Plank-
Rychlo solution, and then embedded in paraffin. Serial sec-
tions were cut at 4 mm, and stained with hematoxylin–eosin
and silver impregnation.
Using a light microscope, the absorption of b-TCP gran-
ules and the formation of bone were graded as follows.18 For
hematoxylin–eosin staining, granules were not surrounded
by cells or newly forming bone (grade 1); granules were
surrounded by osteoblasts and=or osteoclasts (grade 2); and
granules were surrounded by newly forming bone (grade 3).
For silver impregnation staining, granules were not com-
pletely surrounded by collagen fibrils (grade 1); granules
were completely surrounded by collagen fibrils (grade 2);
and granules were completely eroded with reticulated col-
lagen fibrils (grade 3). All the b-TCP granules in a whole
section were classified according to the three grades. The
rates of each grade were then calculated.
Statistics
Results are expressed as the mean SE. The statistical
analysis was first performed by the analysis of variance
(ANOVA), and if there was a significant difference among
samples, Turkey’s post hoc test was performed for multiple
comparisons. The Student’s t-test was carried out to compare




The first screening, of 200 potential biomaterials for the
filter, was based on the parameters described in the Materials
and Methods section. Forty materials were then selected for
the second screening using swine bone marrow cells (n¼ 2).
Ten biomaterials showed CFU counts of more than 10, and
were selected for the third screening by CFU assay (n¼ 3), of
which six preceded to the fourth and last screening (n¼ 3).
Finally, a rayon–polyethylene nonwoven fabric was selected
as the material for the filter (Supplemental Fig. S1, available
online at www.liebertonline.com). First, the optimum ve-
locity of filtration was determined by comparing CFU counts
of cells in the collected and flow-through fractions. A ve-
locity of 2.5mL=min was chosen for further experiments (Fig.
1C). Electron microscopic analysis confirmed the binding of
swine bone marrow cells and their detachment under ret-
rograde flow (Fig. 1D, a and b).
Selective collection of BMSCs by the device
To analyze the device’s selectivity, cultured human
BMSCs or peripheral leukocytes were applied to it, and the
cells in the collected fraction and flow-through fractions were
enumerated (Fig. 2B). More than 90% of BMSCs were col-
lected in the collected fraction, compared to only 28% of
peripheral leukocytes (Fig. 2B). This selectivity was also ob-
served when equal numbers (1106) of BMSCs and periph-
eral leukocytes were mixed and then applied to the device
(Fig. 2C). Because BMSCs and peripheral leukocytes differ in
size, we could distinguish between them in the cell counting
chamber (Fig. 2A). Approximately 80% of BMSCs were
collected in the collected fraction, and an almost equal per-
centage of peripheral leukocytes were collected in the flow-
through fraction (Fig. 2C). More than 90% of CD44þ cells
were collected with the device, leaving almost no CD44þ
cells in the flow-through fraction, whereas less than 20% of
CD45þ cells were collected (Fig. 2D). These results suggested
the selective collection of BMSCs by the device.
FIG. 2. Selective collection of bone marrow stromal cells (BMSCs) with CFUs by the device. (A) Selective counting of BMSCs
and peripheral leukocytes. BMSCs and peripheral leukocytes differed in morphology in the cell counting chamber (left two
photos). After the mixing of the two types of cells (middle) and application of the device, each type of cell in the collected
(right upper) or flow-through (right lower) fraction was numerated. Arrow, cultured BMSCs; arrowhead, peripheral leu-
kocytes. (B) Collection efficacy for human BMSCs (black box) and peripheral leukocytes (gray box). Each type of cell was
applied to the device separately, and collection efficacy was calculated from the number of cells in the collected and flow-
through fractions. (C) Collection efficacy for human BMSCs (black box) and peripheral leukocytes (gray box). Equal numbers
of BMSCs and peripheral leukocytes were mixed and applied to the device. Collection efficacy was calculated from the
number of cells in the collected and flow-through fractions. (D) Collection efficacy for CD44 (hatched box) and CD45þ (dotted
box) cells. Equal numbers of BMSCs and peripheral leukocytes were mixed and applied to the device. Cells positive for CD44
or CD45 in the collected or flow-through fraction were numerated by fluorescence-activated cell sorting (FACS), and col-
lection efficacy was calculated from the number of positive cells in the cell mixture before the treatment. (E) Collection
efficacy for mononuclear cells (MNCs) from canine bone marrow. **p< 0.01 (F) Total number of CFUs derived from canine
MNCs collected in the collected and flow-through fractions. From the results on collection efficacy and number of CFUs, the
total number of CFUs was calculated. **p< 0.01. (G) Collection efficacy for MNCs from human bone marrow. (H) Total
number of CFUs derived from human MNCs collected in the collected and flow-through fractions. **p< 0.01.
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Selective collection of colony-forming cells
from bone marrow by the device
Next, the selectivity of the device was analyzed using cells
derived from canine (Fig. 2E, F) and human (Fig. 2G, H) bone
marrow. In both cases, most erythrocytes passed through the
filter and were collected in the flow-through fraction. Only a
few were found in the collected fraction (data not shown).
For canine bone marrow, the number of MNCs was sig-
nificantly smaller in the collected fraction than in the
FIG. 3. Device selectively prepares MNCs with CFUs. Collection efficacy for MNCs (white box) and erythrocytes (black
box) isolated with each method from canine (A) and human (B) bone marrow. D, S, or F indicates each method described in
Materials and Methods section. **p< 0.01. Number of CFUs derived from equal numbers (2.5105) of MNCs isolated by each
method from canine (C) and human (D) bone marrow. Total number of CFUs derived from equal amounts of canine (E) and
human (F) bone marrow using each method. **p< 0.01. (G) Processing time for each method. **1p< 0.01; **2p< 0.01.
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flow-through fraction ( p¼ 0.002; Fig. 2E). The number of
CFUs, however, was much higher in the collected fraction
( p< 0.001; Fig. 2F). For human bone marrow, the number of
MNCs in the collected and flow-through fraction did not
differ (Fig. 2G). However, the number of CFUs was much
higher in the collected fraction than in the flow-through
fraction ( p< 0.001; Fig. 2H). These results indicated the se-
lective collection of CFUs by the device.
Comparison of method D with methods S and F
The biological properties of cells isolated by each of the three
methods were compared. First, we compared the collection
efficacy of method D with that of method S or F. ANOVA
revealed significant differences among the collection efficacies
for MNCs (canine, p¼ 0.024; human, p¼ 0.0002). Comparisons
between individual methods were then carried out using
Turkey’s post hoc test. For canine bone marrow, the collection
efficacy for MNCs was significantly lower with method D
(20.7 4.2%) than method S (41.6 1.6%) ( p< 0.01; Fig. 3A),
and the same between method D and method F (16.8 14.0%)
(Fig. 3A). As for contamination by erythrocytes, method S
showed larger numbers than method D or F. For human bone
marrow, there was no difference in collection efficacy between
methodD (40.5 14.5%) andmethod S (43.9 10.8%) (Fig. 3B),
and method F (7.3 1.8%) was significantly less efficient than
method D ( p< 0.01; Fig. 3B). The number of contaminating
RBCswas again high with method S (Fig. 3B). Next, theMNCs
collected by each method were seeded on plastic dishes, and
the number of CFUs was counted 14 days later. ANOVA in-
dicated no significant difference among the numbers of CFUs
of MNCs prepared by the three methods in canine ( p¼ 0.40)
and human bone marrow ( p¼ 0.95) (Fig. 3C, D). From the
results on collection efficacy and number of CFUs, the total
number of CFUs isolated frombonemarrowwas calculated for
each method. In the case of canine bone marrow, the total
number of CFUs with method D (10.1 0.2) was equivalent to
that with method S (11.7 4.7) and much larger than that with
methodF, but not significant (6.6 0.1) (Fig. 3E). Similar results
were obtained with human bone marrow cells. The total
number of CFUs with method D (20.3 9.4) was equivalent to
that withmethod S (22.3 4.4), andmuch larger than that with
method F (3.6 1.0) ( p< 0.01; Fig. 3F). These results indicated
that the device collected colony-forming cells from bone mar-
rowwith an efficacy equal to that of current methods requiring
centrifugation. In addition, the processing time for method D
(8.4 1.1min; Fig. 3G) was significantly shorter than that for
the other methods (method S, 18.8 2.9min; method F,
56.5 3.4min) (ANOVA, p< 0.001; Turkey’s post hoc test,
p< 0.01; Fig. 3G).
Expression of MSC markers in isolated BMSCs
To compare the cell population isolated by each of the three
methods, the expression of cell surfacemarkerswas analyzed by
fluorescence-activated cell sorting (FACS). Because a combina-
tion ofmarkers ismore reliable, we focused onCD10þ=CD271þ,
CD90þ=CD271þ, or CD106þ=STRO-1þ double-positive cells.
The CD90þ=CD271þ and the CD106þ=STRO-1þ populations
were significantly larger among cells collected bymethodD than
those collected by method S or method F (ANOVA, p< 0.001;
Turkey’s post hoc test, p< 0.01 for CD90þ=CD271þ, p< 0.05 for
CD106þ=STRO-1þ, respectively; Fig. 4A, B).
Differentiation potential of isolated BMSCs
To analyze their potential to differentiate, the BMSCs
isolated by each of the methods were propagated on culture
FIG. 4. Device selectively prepares MNCs, which express mesenchymal marker. (A) FACS analysis of CD106 and STRO-1
on MNCs isolated by each method. (B) Fraction of cells double-positive for mesenchymal stem cell (MSC) markers among
MNCs isolated by each method. **1,**2p< 0.01; *1,*2,*3p< 0.05.
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dishes and incubated for 2 weeks under standard growth
conditions for MSCs. They were then induced to undergo
osteogenesis, adipogenesis, and chondrogenesis. The mor-
phology of the cells isolated by each of the methods was
almost the same for both canine (Supplemental Fig. S2A,
available online at www.liebertonline.com) and human
(Fig. 5A) BMSCs. There was no difference in growth profile
among the three methods in canine (Supplemental Fig. S2B,
available online at www.liebertonline.com) or human (Fig.
5B) BMSCs. Osteogenic differentiation potential was evalu-
ated with histochemical (alizarin red staining; Fig. 5C),
mRNA expression (expression of the ALP and COL1A1
genes; Fig. 5D), and biochemical (calcium content; Fig. 5E)
analyses. There was no significant difference among the cells
isolated by each of the three methods (ANOVA, p¼ 0.61).
Similar results were observed in adipogenic differentiation
FIG. 5. Growth and differentiation potential of human BMSCs isolated by each method. The same numbers of BMSCs
isolated by the three methods from human bone marrow were propagated on culture dishes for 2 weeks under standard
conditions. (A) Microscopic views of cultured BMSCs isolated by each method. Magnification, 100. Scale bars¼ 100mm. (B)
Growth of cultured BMSCs isolated by each method. , Method D;~, method S;&, method F. (C) Differentiation potential
of BMSCs isolated by each method. Osteogenic differentiation was analyzed by alizarin red staining. Magnification, 100.
Scale bars¼ 100mm. Adipogenic differentiation was analyzed by oil red-O staining. Magnification, 100. Scale bars¼ 100 mm.
Chondrogenic differentiation was analyzed by alcian blue staining. Magnification, 40. Scale bars¼ 300 mm. (D) Expression of
bone-related genes before and after osteogenic induction. ALP, alkaline phosphatase. (E) Ca content after osteogenic in-
duction. Ca, calcium. (F) Expression of fat-related genes before and after adipogenic induction. ADP, adipsin; FABP, fatty
acid–binding protein; PPARg, peroxisome proliferator-activated receptor gamma. (G) TG content after adipogenic induction.
TG, triglyceride. (H) Expression of cartilage-related genes before and after chondrogenic induction. AGC, aggrecan. (I) GAG
content after chondrogenic induction. GAG, glycosaminoglycan.
FIG. 6. Regeneration of bone tissues by cells isolated with the device. Data for six dogs at 4 weeks after the operation are
presented. Frontal (A) and sagittal (B) views of micro-computed tomography. (C) Morphometrical analyses. The results of X-
ray and micro-computed tomography were evaluated using the criteria described in the Materials and Methods section. Bone
weight and volume were actually measured. **p< 0.01; *p< 0.05. CHR, carpal height ratio. (D) Histological analyses by
hematoxylin–eosin staining. Magnification, 100. Scale bar¼ 500mm. (E) Fraction of regenerated bone tissue of each grade.
Grade 1, white box; grade 2, gray box; grade 3, black box. *p< 0.05. (F) Histological analyses using silver impregnation
staining. Magnification, 200. Scale bar¼ 200mm. (G) Fraction of b-tricalcium phosphate with integrated collagen fibers of
each grade. Grade 1, white box; grade 2, gray box; grade 3, black box. *p< 0.05.
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(ANOVA, p¼ 0.41; Fig. 5C, F, G) and chondrogenic differen-
tiation (ANOVA, p¼ 0.97; Fig. 5C, H, I). Same results were
obtained in the analyses of canine BMSCs (Supplemental Fig.
S2C, available online at www.liebertonline.com). These results
suggested that BMSCs isolated by each of the three methods
had the multidirectional differentiation potential of MSCs.
Regeneration of bone tissues by cells isolated
with the device
To confirm the in vivo osteogenic potential of cells collected
with the device, we used the cells to regenerate bone tissues in
a model of osteonecrosis using canine scapho-lunates, which
we established previously.15 Micro-CT findings at 4 weeks
after the operation indicated bone regeneration to be more
prominent on the BMSC side than control side in all cases
(Fig. 6A, B). Carpal height ratio and the Sta˚hl index calculated
from plain X-rays show the degree of collapse of scapho-
lunate bone. Both parameters were significantly higher on the
BMSC side than control side (Fig. 6C). Total volume and bone
volume were analyzed from the micro-CT data. Bone volume
and therefore bone ratio were greater on the BMSC side (Fig.
6C). Both actual weight and volume were also significantly
higher on the BMSC side (Fig. 6C). These quantitative analy-
ses suggested that the application of BMSCs prepared by the
device contributed significantly to bone regeneration.
After the physical and radiological examinations, samples
were processed for histological analyses. Microscopic find-
ings of samples taken from the control side showed that a
large amount of b-TCP remained unabsorbed, although
multinucleated giant cells were found adjacent to b-TCP. In
contrast, abundant new bone with the active absorption of b-
TCP by multinucleated giant cells was found on the BMSC
side (Fig. 6D). The extent to which b-TCP was absorbed as
new bone formed was scored using criteria described in the
Materials and Methods section. The grade 3 fraction was
significantly larger on the BMSC side ( p¼ 0.032; Fig. 6E).
To analyze the interaction between the prepared cells and
b-TCP, silver impregnation staining was performed (Fig. 6F).
The staining shows the invasion of collagen fibers into bio-
degradable materials. Collagen fibers in b-TCP granules
adjacent to regenerated bone tissue were abundant on the
BMSC side, but rare on the control side (Fig. 6F). Quantita-
tive analyses showed the extent of the invasion to be sig-
nificantly greater on the BMSC side ( p¼ 0.034; Fig. 6G).
These results suggested that BMSCs prepared using the de-
vice enhanced bone regeneration in vivo.
Discussion
Bone marrow cells consist of two types of MNCs: hema-
topoietic cells including hematopoietic stem cells, and stro-
mal cells including MSCs. Approximately 99% of MNCs in
bone marrow belong to the former population, and among
the stromal cells, less than 5% have multidirectional differ-
entiation potential compatible with the concept of MSCs.
Therefore, the proportion of MSCs among bone marrow
MNCs is estimated at less than 0.05%.19 To obtain BMSCs
including MSCs from bone marrow, it is essential to separate
the hematopoietic MNCs.
Takenaka developed a novel filter composed of nonwoven
fabrics to trap peripheral leukocytes for the treatment of au-
toimmune disease.10 Because erythrocytes are deformed,
which allows them to pass through small pores and have low
adhesiveness, they can be separated from MNCs by the fil-
ter.10 They used fibers 1.7 mm in diameter, because all the
leukocytes were trapped when the fiber was less than 3mm in
diameter.10 This filter, however, is not applicable to the sep-
aration of MSCs from hematopoietic MNCs, both of which
will be captured, making it difficult to separate them by cell
size. Therefore, we used fibers 15 mm in diameter with greater
affinity for BMSCs than hematopoieticMNCs.MSCs aremore
adherent than hematopoietic cells.4,19 MSCs adhere much
more tightly to highly hydrophilic and rough surfaces than to
hydrophobic and smooth surfaces.20 The contact angle of the
nonwoven fabric in the current device is estimated to be 208,
which is highly hydrophilic and may make it possible to trap
MSCs in the device. This adherent trapping method may
prevent excess shearing stress caused by the flow. Cells iso-
lated by the device showed no increase in bradykinine or
lactate dehydrogenase (LDH) (data not shown). In addition,
mRNA expression of the p16 and p53 genes was not increased,
and the karyotype showed no abnormalities (data not shown).
In terms of its potential clinical applications, the device
has several advantages. The filter is composed of rayon and
polyethylene. Rayon is used for the dialysis membranes of
hemodialyzers and known to decrease platelet activity.21
Polyethylene is a biomaterial employed in total hip replace-
ment and as a scaffold for tissue engineering.22 Therefore, all
the materials are safe for clinical use. The isolation of BMSCs
in a closed system is a major advantage of this device.
Centrifugation requires mixing with an appropriate solution,
which has to be performed in an open system. Current
guidelines require the centrifugation process to be performed
in an isolated area with specialized equipment. Because all
steps can be done in a closed system, the device can isolate
BMSCs from bone marrow on the operation table. Further,
processing time is shorter than for the other two methods
(Fig. 3G), which may help to reduce cell death during the
isolation procedures. In addition, the method does not re-
quire special skills, which will help to obtain constant results
and also be an advantage for clinical application.
We have shown that in terms of differentiation potential,
the cells isolated using the device were equivalent to those
prepared by current methods using centrifugation. The total
number of CFUs obtained from bone marrow was equal to
that achieved with method S and higher than that obtained
with method F, suggesting that the device recovers almost all
cells with the ability to form CFUs. FACS analyses showed
that the method was superior to others in terms of the re-
covery of the MSC marker-positive population. CD10, CD44,
CD90, CD106, and STRO-1 are considered surface markers of
MSCs,13,23 and, recently, CD271 was identified as a marker
of MSCs.24 The fractions of CD90þ=CD271þ cells were larger
among cells collected using the device than those isolated
with the other two methods (Fig. 4). The CD106þ=STRO-1þ
fraction (1.61 0.37%; Fig. 4) was even larger than that col-
lected by FACS (1.4 0.3%),25 which has a risk of microbial
contamination and unfavorable effects. We have no clear ex-
planation for this selective collection. BecauseCD106þ=STRO-1þ
cells attach to plastic dish efficiently and have high colony-
forming activity,26 one possibility is that CD106þ=STRO-1þ cells
have high affinity to the filter materials used in the device. Fi-
nally, we have shown that the direct application of the trapped
cells without ex vivo cultivation assisted the regeneration of bone
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tissue in vivo (Fig. 6), although the role of transplanted cells may
not be simply to reconstitute bone tissues by themselves but also
to produce cytokines stimulating host cells,15 suggesting that
BMSCs collected with the new device on the operating table
could be used for conditions requiring an acceleration of bone
regeneration such as the nonunion of bone fractures.
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